Raymond James Financial Services Advisors, Inc. Agenus Inc Transaction History

Raymond James Financial Services Advisors, Inc.

$73.5 Billion
Q3 2024

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	SELL	$0.53 - $0.93 $6,369 - $11,176	-12,018 Reduced 45.9%	14,164 $8,000
Q4 2023 Jan 16, 2024	BUY	$0.63 - $1.14 $16,494 - $29,847	26,182 New	26,182 $21,000
Q1 2023 Apr 14, 2023	BUY	$1.45 - $2.95 $7,998 - $16,272	5,516 Added 38.14%	19,977 $30,000
Q4 2022 Feb 08, 2023	SELL	$2.02 - $3.25 $92 - $149	-46 Reduced 0.32%	14,461 $34,000
Q3 2022 Oct 25, 2022	SELL	$1.96 - $3.14 $1,960 - $3,140	-1,000 Reduced 6.45%	14,507 $30,000
Q1 2022 May 11, 2022	SELL	$2.35 - $3.47 $1,809 - $2,671	-770 Reduced 4.73%	15,507 $38,000
Q4 2021 Feb 08, 2022	BUY	$2.92 - $5.74 $47,528 - $93,429	16,277 New	16,277 $52,000

Others Institutions Holding AGEN

# of Institutions

Shares Held

2.07M

Call Options Held

Put Options Held

View Full List

About AGENUS INC

Ticker AGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 283,163,008
Market Cap $4.73B
Description
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...

More about AGEN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.

Account